Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

dl42 Jan. 2 at 9:54 PM

$GOSS relatively new here, my take is Ph2 was successful w/ a patient population that was not setup for success. The Ph3 sounds like it was designed for success. Thoughts on Ph3 having better outcomes than Ph2?

1 · Reply

Finnish_boy Jan. 2 at 9:33 PM

$GOSS Why stock down 25% from highs. I have no idea. Why stock up 35% from october. I dont know. Today overall red day. I dont care any bearish post bc i have identified all bear theses. And every bearish thesis lack of understanding. That's why these kind of posts are no news to me ⬇️ this stock is bear trap. And that guy lifted already his PoS to 55% from 33% bc he has no idea what he is talking about. And if PoS was in reality 55%, stock would be strong buy now. Imo PoS around 90%

0 · Reply

Tubular9988 Jan. 2 at 8:51 PM

$GOSS ive been positive on Goss but the price action on volume is very concerning. with a ph 3 with such a binary outcome, there are ph 3 result leaks. the same happened with nktr. it broke down before results which were negative. smmt broke to the upside before results which were positive.

1 · Reply

StockScubaDiver Jan. 2 at 7:03 PM

$GOSS

0 · Reply

Finnish_boy Jan. 2 at 6:13 PM

$GOSS All bios are down today. I think next week we hit $3.4 Analysts make some notes and pump the stock. And in Feb about 25m result and SP skyrockets to $8

1 · Reply

sp08 Jan. 2 at 5:56 PM

$GOSS look like they will take it back to $2.40 level..

0 · Reply

Finnish_boy Jan. 2 at 3:18 PM

$GOSS I have buy order at $2.8.. already enough big position but i try fish little more shares.. i think SP hits $4 before the readout.. $2.8 ->$4 over 40% profit

2 · Reply

dirkflute Jan. 2 at 3:15 PM

$GOSS load up

0 · Reply

Finnish_boy Jan. 2 at 11:17 AM

$GOSS Great work.. bottom indicator.

1 · Reply

Dude12345 Jan. 2 at 10:20 AM

$GOSS dis a 0 sorry

0 · Reply

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 24, 2025, 4:01 PM EST - 5 weeks ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 5, 2025, 4:01 PM EST - 2 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Sep 25, 2025, 7:41 AM EDT - 3 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:31 AM EDT - 3 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 22, 2025, 7:31 AM EDT - 3 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 9:50 AM EDT - 4 months ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Aug 29, 2025, 7:31 AM EDT - 4 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 5, 2025, 4:01 PM EDT - 5 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 16, 2025, 7:31 AM EDT - 7 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

May 15, 2025, 9:30 PM EDT - 8 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:01 PM EDT - 8 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 12, 2025, 4:01 PM EDT - 8 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 7, 2025, 4:01 PM EDT - 8 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Mar 13, 2025, 4:01 PM EDT - 10 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 7:42 PM EST - 11 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 11 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Mar 17, 2023, 7:31 AM EDT - 3 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Jan 30, 2023, 4:48 AM EST - 3 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Dec 8, 2022, 1:27 PM EST - 3 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 6, 2022, 8:19 AM EST - 3 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 7:15 AM EST - 3 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

dl42 Jan. 2 at 9:54 PM

1 · Reply

Finnish_boy Jan. 2 at 9:33 PM

0 · Reply

Tubular9988 Jan. 2 at 8:51 PM

1 · Reply

StockScubaDiver Jan. 2 at 7:03 PM

$GOSS

0 · Reply

Finnish_boy Jan. 2 at 6:13 PM

$GOSS All bios are down today. I think next week we hit $3.4 Analysts make some notes and pump the stock. And in Feb about 25m result and SP skyrockets to $8

1 · Reply

sp08 Jan. 2 at 5:56 PM

$GOSS look like they will take it back to $2.40 level..

0 · Reply

Finnish_boy Jan. 2 at 3:18 PM

$GOSS I have buy order at $2.8.. already enough big position but i try fish little more shares.. i think SP hits $4 before the readout.. $2.8 ->$4 over 40% profit

2 · Reply

dirkflute Jan. 2 at 3:15 PM

$GOSS load up

0 · Reply

Finnish_boy Jan. 2 at 11:17 AM

$GOSS Great work.. bottom indicator.

1 · Reply

Dude12345 Jan. 2 at 10:20 AM

$GOSS dis a 0 sorry

0 · Reply

MoneyGroupLLC Jan. 1 at 4:42 AM

Enter: $GOSS Calls Strike Price: $4 Expiry Date: FEB 20 2026 Buy in Price: $0.90 - $1.25 Sell Price: $1.82 Profit : +102% (Turn every $1 into $2.02) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Finnish_boy Dec. 31 at 4:01 PM

$GOSS LMAO.. "lotta short covering in February or already in January"

0 · Reply

Finnish_boy Dec. 31 at 3:53 PM

$GOSS If PoS would be 55% in reality, this is "BUY" bc upside 200% downside 100%. And I think reality is nearer 90% than 50%. that's why i am extremely bullish. But DYOR. You can lose all money. In my case i have also 10% risk to lose all money. Shit can happen or not. Never know. Risk management very important.

0 · Reply

Finnish_boy Dec. 31 at 3:49 PM

$GOSS PoS was 33% yesterday, now all of sudden 55%. very sharp minds lifted PoS overnight over 20%. very clever.

0 · Reply

Finnish_boy Dec. 31 at 3:47 PM

$GOSS These accounts are always guessing.. everyone is guessing. DYOR!

0 · Reply

Finnish_boy Dec. 31 at 3:46 PM

$GOSS 😂

0 · Reply

Finnish_boy Dec. 31 at 2:36 PM

$GOSS Yes exactly. It's all about baselines. Sotatercept is faster but more dangerous drug overall, it increases hemoglobin, and effect wane after 1 year.

1 · Reply

Finnish_boy Dec. 30 at 11:15 PM

$GOSS Avid knows the story

1 · Reply

Finnish_boy Dec. 30 at 10:38 PM

$GOSS Never mind. they will learn in February.

0 · Reply

Finnish_boy Dec. 30 at 10:35 PM

$GOSS It's crazy when they compare Seralutinib to Imatinib.. biggest mistake that can be done

0 · Reply

Finnish_boy Dec. 30 at 10:24 PM

$GOSS Here is the big part of short thesis 😂mgt explained this in december 2023.

0 · Reply

Finnish_boy Dec. 30 at 10:18 PM

$GOSS KOLs and mgt think OLE data is amazing when they understand the data😂 Everyone can read the data points. But you need to understand the data also.

0 · Reply

Market Cap	717.51M
Revenue (ttm)	114.70M
Net Income (ttm)	-56.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.29%
Debt to Equity Ratio	0.00

Volume	3,854,000
Avg Vol	3,561,656
Day's Range	N/A - N/A
Shares Out	231.46M
Stochastic %K	8%
Beta	1.92
Analysts	Strong Sell
Price Target	$9.50